{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:29:44Z","timestamp":1793640584340,"version":"4.5.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40257-026-01085-4","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:23:42Z","timestamp":1791998622000},"page":"1161-1175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes and Predictors of Sustained Response After Dose Tapering of Targeted Therapies in Moderate-to-Severe Atopic Dermatitis: A Systematic Review"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4899-9082","authenticated-orcid":false,"given":"Marina","family":"Mordehachvili Burl\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyria","family":"de Oliveira Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Ximenes","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Valeriano","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe K.","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tsoukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"1085_CR1","first-page":"1","volume":"00","author":"A Wollenberg","year":"2025","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: living update. J Eur Acad Dermatol Venereol. 2025;00:1\u201330.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1085_CR2","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1001\/jamadermatol.2024.2517","volume":"160","author":"CM Boesjes","year":"2024","unstructured":"Boesjes CM, Kamphuis E, de Graaf M, et al. Long-term effectiveness and reasons for discontinuation of dupilumab in patients with atopic dermatitis. JAMA Dermatol. 2024;160(10):1044\u201355.","journal-title":"JAMA Dermatol"},{"issue":"11","key":"1085_CR3","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/jdv.20229","volume":"38","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(11):2139\u201348. https:\/\/doi.org\/10.1111\/jdv.20229.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1085_CR4","doi-asserted-by":"publisher","first-page":"745.e1","DOI":"10.1016\/j.jaad.2025.05.1386","volume":"93","author":"DMR Davis","year":"2025","unstructured":"Davis DMR, Frazer-Green L, Alikhan A, et al. Focused update: guidelines of care for the management of atopic dermatitis in adults. J Am Acad Dermatol. 2025;93(3):745.e1-745.e7. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1386.","journal-title":"J Am Acad Dermatol"},{"key":"1085_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1085_CR6","unstructured":"R Core Team. R: a language and environment for statistical computing (Version 4.2.1) [software]. R Foundation for Statistical Computing. https:\/\/www.R-project.org\/."},{"key":"1085_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1085_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"1085_CR9","unstructured":"Neumann I, Sch\u00fcnemann H, editors. The GRADE Book. Version 1.0. Milan: GRADE Working Group; 2024 [updated 2024 Sep]. https:\/\/book.gradepro.org."},{"issue":"1","key":"1085_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.075.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1085_CR11","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s13555-022-00764-4","volume":"12","author":"MJ Gooderham","year":"2022","unstructured":"Gooderham MJ, Girolomoni G, Moore JO, et al. Durability of response to abrocitinib in patients with moderate-to-severe atopic dermatitis after treatment discontinuation in a phase 2b trial. Dermatol Ther. 2022;12(9):2077\u201385. https:\/\/doi.org\/10.1007\/s13555-022-00764-4.","journal-title":"Dermatol Ther"},{"key":"1085_CR12","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.0411","author":"S Deng","year":"2025","unstructured":"Deng S, Fu J, Chen X, et al. Abrocitinib treatment modes: impact on prognosis and relapse rates in atopic dermatitis. Dermatitis. 2025. https:\/\/doi.org\/10.1089\/derm.2024.0411.","journal-title":"Dermatitis"},{"issue":"2","key":"1085_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/bjd\/ljac057","volume":"188","author":"K Reich","year":"2023","unstructured":"Reich K, Simpson E, Wollenberg A, et al. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. Br J Dermatol. 2023;188(2):208\u201317. https:\/\/doi.org\/10.1093\/bjd\/ljac057.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1085_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2190430","volume":"34","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, Werfel T, Barbarot S, et al. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial. J Dermatolog Treat. 2023;34(1):2190430. https:\/\/doi.org\/10.1080\/09546634.2023.2190430.","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"1085_CR15","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1007\/s13555-023-01016-9","volume":"13","author":"MJ Cork","year":"2023","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, et al. Dupilumab safety and efficacy in a phase III open-label extension trial in children 6-11 years of age with severe atopic dermatitis. Dermatol Ther (Heidelb). 2023;13(11):2697\u2013719. https:\/\/doi.org\/10.1007\/s13555-023-01016-9.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1085_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","volume":"23","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Guttman-Yassky E, Paller AS, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365\u201383. https:\/\/doi.org\/10.1007\/s40257-022-00683-2.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1085_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm M, Simpson EL, Tha\u00e7i D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131\u201343. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3617.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1085_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2235041","volume":"34","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Dal Bello G, Gori N, et al. Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study. J Dermatolog Treat. 2023;34(1):2235041. https:\/\/doi.org\/10.1080\/09546634.2023.2235041.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1085_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5021\/ad.24.084","volume":"37","author":"H Kim","year":"2025","unstructured":"Kim H, Oh S, Noh H, et al. Appropriate injection intervals of dupilumab in patients with adult atopic dermatitis: a step toward developing guidelines for daily practice. Ann Dermatol. 2025;37(1):39\u201345. https:\/\/doi.org\/10.5021\/ad.24.084.","journal-title":"Ann Dermatol"},{"key":"1085_CR20","doi-asserted-by":"publisher","first-page":"adv00731","DOI":"10.2340\/actadv.v102.295","volume":"102","author":"S Miyamoto","year":"2022","unstructured":"Miyamoto S, Imai Y, Natsuaki M, et al. Long-term remission of atopic dermatitis after discontinuation of dupilumab. Acta Derm Venereol. 2022;102:adv00731. https:\/\/doi.org\/10.2340\/actadv.v102.295.","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"1085_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15933","volume":"35","author":"C Patruno","year":"2022","unstructured":"Patruno C, Potestio L, Fabbrocini G, Napolitano M. Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis. Dermatol Ther. 2022;35(12):e15933. https:\/\/doi.org\/10.1111\/dth.15933.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1085_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/bjd\/ljad159","volume":"189","author":"LS Spekhorst","year":"2023","unstructured":"Spekhorst LS, Boesjes CM, Loman L, et al. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry. Br J Dermatol. 2023;189(3):327\u201335. https:\/\/doi.org\/10.1093\/bjd\/ljad159.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1085_CR23","doi-asserted-by":"publisher","first-page":"e1426","DOI":"10.1111\/jdv.19348","volume":"37","author":"V S\u00e1nchez-Garc\u00eda","year":"2023","unstructured":"S\u00e1nchez-Garc\u00eda V, Navarro-Trivi\u00f1o FJ, Silvestre JF. Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(12):e1426\u20139. https:\/\/doi.org\/10.1111\/jdv.19348.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1085_CR24","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1111\/jdv.19528","volume":"38","author":"C Valente","year":"2024","unstructured":"Valente C, Farinha P, Duarte B. Extending dupilumab dosing intervals in atopic dermatitis: a prospective observational study in a South European tertiary hospital. J Eur Acad Dermatol Venereol. 2024;38(2):e193\u20134. https:\/\/doi.org\/10.1111\/jdv.19528.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1085_CR25","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.387","author":"J Vieira","year":"2025","unstructured":"Vieira J, Marcelino J, Proen\u00e7a M, et al. Successful dupilumab dose spacing in controlled severe atopic dermatitis and predictive factors. Eur Ann Allergy Clin Immunol. 2025. https:\/\/doi.org\/10.23822\/EurAnnACI.1764-1489.387.","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"8","key":"1085_CR26","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s13555-024-01226-9","volume":"14","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Wollenberg A, Stein Gold L, et al. Patients with moderate-to-severe atopic dermatitis maintain stable response with no or minimal fluctuations with 1 year of lebrikizumab treatment. Dermatol Ther (Heidelb). 2024;14(8):2249\u201360. https:\/\/doi.org\/10.1007\/s13555-024-01226-9.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1085_CR27","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","volume":"188","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljad022.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1085_CR28","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/bjd\/ljae439","volume":"192","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Bewley A, Hong HC, et al. Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2025;192(3):410\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljae439.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1085_CR29","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s13555-025-01405-2","volume":"15","author":"FJ Melgosa Ramos","year":"2025","unstructured":"Melgosa Ramos FJ, Alarc\u00f3n SS, Motilla JMS, Mercader P. Long-term efficacy and potential predictors of tralokinumab dose optimization in elderly patients: a multicentre study. Dermatol Ther (Heidelb). 2025;15(5):1251\u20137. https:\/\/doi.org\/10.1007\/s13555-025-01405-2.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1085_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40257-025-00923-1","volume":"26","author":"Z Tong","year":"2025","unstructured":"Tong Z, Zeng X, Huang F, et al. Upadacitinib dose reduction regimen in elderly patients with atopic dermatitis, guided by treat-to-target consensus recommendations. Am J Clin Dermatol. 2025;26(3):437\u201347. https:\/\/doi.org\/10.1007\/s40257-025-00923-1.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1085_CR31","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/ddg.15688","volume":"23","author":"H Wu","year":"2025","unstructured":"Wu H, Zhu J, Yang N, et al. Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab. JDDG J Dtsch Dermatol Ges. 2025;23(6):702\u201310. https:\/\/doi.org\/10.1111\/ddg.15688.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"9","key":"1085_CR32","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.jid.2023.03.1659","volume":"143","author":"C Dekkers","year":"2023","unstructured":"Dekkers C, der Wal MMV, El Amrani M, et al. Biological tipping point in patients with atopic dermatitis treated with different dosing intervals of dupilumab. J Invest Dermatol. 2023;143(9):1822-1825.e3. https:\/\/doi.org\/10.1016\/j.jid.2023.03.1659.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1085_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061392","volume":"10","author":"HA Kader","year":"2021","unstructured":"Kader HA, Azeem M, Jwayed SA, et al. Current insights into immunology and novel therapeutics of atopic dermatitis. Cells. 2021;10(6):1392. https:\/\/doi.org\/10.3390\/cells10061392.","journal-title":"Cells"},{"issue":"14","key":"1085_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411380","volume":"24","author":"JG Gatmaitan","year":"2023","unstructured":"Gatmaitan JG, Lee JH. Challenges and future trends in atopic dermatitis. Int J Mol Sci. 2023;24(14):11380. https:\/\/doi.org\/10.3390\/ijms241411380.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1085_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21\u201340. https:\/\/doi.org\/10.1038\/s41573-021-00266-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"55","key":"1085_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe2749","volume":"6","author":"C Bangert","year":"2021","unstructured":"Bangert C, Rindler K, Krausgruber T, et al. Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4R\u03b1 blockade. Sci Immunol. 2021;6(55):eabe2749. https:\/\/doi.org\/10.1126\/sciimmunol.abe2749.","journal-title":"Sci Immunol"},{"key":"1085_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1875991","volume":"17","author":"Z Qiao","year":"2026","unstructured":"Qiao Z, Tang L, Luo N, et al. From clinical remission to biological stability in psoriasis: an antigen-blood-tissue framework for relapse stratification. Front Immunol. 2026;17:1875991. https:\/\/doi.org\/10.3389\/fimmu.2026.1875991.","journal-title":"Front Immunol"},{"issue":"4","key":"1085_CR38","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40257-025-00949-5","volume":"26","author":"D Ranzinger","year":"2025","unstructured":"Ranzinger D, Eyerich K. Disease modification in psoriasis: future prospects for long-term remission. Am J Clin Dermatol. 2025;26(4):477\u201386. https:\/\/doi.org\/10.1007\/s40257-025-00949-5.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1085_CR39","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927\u201340. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.009.","journal-title":"J Allergy Clin Immunol"},{"issue":"10478","key":"1085_CR40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","volume":"405","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(24)02519-4.","journal-title":"Lancet"},{"issue":"1","key":"1085_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2396382","volume":"35","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gold LS, Desai S, et al. Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry. J Dermatolog Treat. 2024;35(1):2396382. https:\/\/doi.org\/10.1080\/09546634.2024.2396382.","journal-title":"J Dermatolog Treat"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01085-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:03:01Z","timestamp":1793638981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01085-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1085"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01085-4","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"24 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data from the included studies are available in the public domain. Patient-level data were not accessed.","order":6,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MMB: Conceptualization, study design, data collection, data interpretation, data analysis, and writing (original\u00a0draft). LR: Data collection, data analysis, and writing (review and editing). BXM: Data interpretation, data analysis, and writing (review and editing). FVZ: Data analysis and writing (review and editing). JKT: Conceptualization, study design, and writing (review and editing). MT: Conceptualization and writing (review and editing). RH: Conceptualization, study design, data interpretation, and writing (review and editing). All authors read and approved the final version.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}